We Offer Worldwide Shipping
Login Wishlist

Hederacolchiside E


  • Brand : BIOFRON

  • Catalogue Number : BN-O1306

  • Specification : 98%(HPLC)

  • CAS number : 33783-82-3

  • Formula : C65H106O30

  • Molecular Weight : 1367.5

  • PUBCHEM ID : 101358459

  • Volume : 5mg

Available on backorder

Checkout Bulk Order?

Catalogue Number


Analysis Method





Molecular Weight



Botanical Source

Structure Type







[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl] (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2S,3R,4S,5S)-4-hydroxy-5-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate



Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point


InChl Key


WGK Germany


HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:33783-82-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.




Inspired by the previously reported neuroprotective activity of hederacolchiside E (1), we synthesized hederacolchiside E for the first time along with eleven of its derivatives. The neuroprotective effects of these compounds were further evaluated against H2O2- and Aβ1-42-induced injury using cell-based assays. The derivatives showed obvious differences in activity due to structural variations, and two of them exhibited better neuroprotective effects than 1 in the Aβ1-42-induced injury model. Compound 7 was the most active derivative and had a relatively simple chemical structure. Moreover, 1 and 7 can significantly reduce the release of lactate dehydrogenase (LDH), level of intracellular reactive oxygen species (ROS) and extent of malondialdehyde (MDA) increase resulting from Aβ1-42 treatment, which demonstrated that these kinds of compounds show neuroprotective effects in Alzheimer’s disease (AD) models via modulating oxidative stress. Compound 7 could be used as promising lead for the development of a new type of neuroprotective agent against AD.

Copyright © 2017 Elsevier Masson SAS. All rights reserved.


Alzheimer's disease; Antioxidation; Hederacolchiside E; Neuroprotective effects; Structure-activity relationship


Synthesis, biological evaluation and structure-activity relationship studies of hederacolchiside E and its derivatives as potential anti-Alzheimer agents.


Li HN1, Liu Y2, Zhang ZP1, Wang ZP1, Hao JZ1, Li FR1, Fan ZF1, Zou LB3, Cheng MS4.

Publish date

2018 Jan 1




A simple, rapid, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was applied to pharmacokinetic study of a neuroactive oleanolic-glycoside saponin, hederacolchiside E from SK-PC-B70M, a standardized extract of Pulsatilla koreana in rat. Rat plasma samples were pretreated by protein precipitation with acetonitrile, eluted from C(18) column, and analyzed using electrospray ionization (ESI)-MS/MS in negative ion mode. Digoxin was used as an internal standard. The standard curves were linear (r>0.997) over the concentration ranges of 2-500 ng/mL. The intra- and inter-day precisions were measured to be below 9% and accuracy between 90 and 111% for all quality control samples at 2, 20, 100, and 500 ng/mL (n=5). The lower limits of quantification (LLOQ) for hederacolchiside E was 2 ng/mL and the limit of detection (LOD) 0.5 ng/mL using 20 microL of plasma sample. Subsequently, hederacolchiside E was determined in rat plasma samples after oral administration of SK-PC-B70M. The mean maximum plasma concentrations of hederacolchiside E were 0.07, 0.13, and 0.36 microg/mL and the mean areas under the plasma concentration versus time curve 0.56, 1.27, and 6.46 microg h/mL at doses of 100, 200, and 400 mg/kg, respectively, which indicated non-linear pharmacokinetic pattern. In conclusion, this method was successfully applied to the pharmacokinetic study of hederacolchiside E after an oral administration of SK-PC-B70M to rats.


LC-MS/MS method for determination of hederacolchiside E, a neuroactive saponin from Pulsatilla koreana extract in rat plasma for pharmacokinetic study.


Yoo HH1, Lee SK, Lim SY, Kim Y, Kang MJ, Kim EJ, Park YH, Im GJ, Lee BY, Kim DH.

Publish date

2008 Dec 15




The root extract of Pulsatilla koreana (Ranunculaceae) has been found to have prominent abilities to reverse scopolamine-induced cognitive impairment in rats, and to increase the viability of human neuroblastoma SK-N-SH cells incubated with amyloid-beta peptide (1 – 42) [A beta (1 – 42)]. In vivo and in vitro activity-guided fractionation studies using solvent-partitioning and subsequent chromatographic separations led to the isolation of hederacolchiside-E, an oleanolic glycoside, as an active ingredient. Administration of hederacolchiside-E (30 and 60 mg/kg body weight, P. O.) increased the step-through latency time in the passive avoidance test as efficiently as tacrine (30 mg/kg, P. O.). The neuroprotective effect of hederacolchiside-E on SK-N-SH cells against the toxicity of A beta (1 – 42) was comparable to that of catechin. These data suggest that hederacolchiside-E might be a good therapeutic candidate for the treatment of Alzheimer’s disease.


Cognition-enhancing and neuroprotective effects of hederacolchiside-E from Pulsatilla koreana.


Han CK1, Choi WR, Oh KB.

Publish date

2007 Jun

Description :

Empty ...